Santo is a biopharmaceutical drug-development company building in vivo gene therapies, particularly for rare diseases and cancers
Santo is a biopharmaceutical drug-development company building in vivo gene therapies, particularly for rare diseases and cancers. Its platforms combine advanced, programmable lentiviral-vector delivery, disease models including organoids and patient-derived xenografts, and lentiviral manufacturing-process optimization. Its pipeline targets underserved indications including neurofibromatosis, meningioma, and malignant mesothelioma.